Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Phase 1(2)

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05303077Not ApplicableCompleted

Study of the Effects of a New Infant Formula Supplemented With a Probiotic Over the Corporal Composition of Infants

Role: collaborator

NCT05029297Phase 3Completed

Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.

Role: collaborator

NCT04326400Unknown

Active Monitoring And Determinants of Incidence Infection of COVDI-19

Role: lead

NCT04043676Phase 2Unknown

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Role: lead

NCT03955380Phase 1Completed

MAD Phase I Study to Investigate Contraloid Acetate

Role: collaborator

NCT03944460Phase 1Completed

SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate

Role: collaborator

All 6 trials loaded